Co-Diagnostics (CODX) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/12/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
Co-Diagnostics, Inc. Reports Second Quarter 2023 Financial Results
August 10, 2023 4:01 PM EDTCo-Dx receives grant awards from the Bill & Melinda Gates Foundation; NIH RADx® Tech to develop tests on our new Co-Dx PCR Home platform
SALT LAKE CITY, Aug. 10, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the quarter ended June 30, 2023.
... More